🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT04248283
Recruiting Not applicable

Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

NCT04248283 · tracked via the Priya Life Science USA tracker
Sponsor
Uromedica
Phase
Not applicable
Started
2021-01-26
Last updated
2026-06-17

Condition(s) studied

Urinary IncontinenceUrinary Incontinence,Stress

Investigational drug(s) / intervention(s)

Adjustable Continence Therapy for Women (ACT)

Adjustable Continence Therapy for Women (ACT): Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately).

Study summary

A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.

Eligibility

Sex
FEMALE
Min age
22 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Female at least 22 years old 2. Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency 3. Provocative pad weight of greater than 11.0 grams 4. Candidate for surgical intervention 5. Negative urinalysis 6. Normal cystourethroscopy 7. Failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note: patients may have failed prior anti-incontinence procedures for SUI (e.g., suspension, sling, or urethral bulking agent) 8. Willing and able to sign informed consent and comply with trial follow-up requirements Exclusion Criteria: 1. Pregnant or lactating 2. Life expectancy of less than 5 years 3. Has uncontrolled diabetes as evidenced by HbA1c over 6.5% and fasting plasma glucose over 130 mg/dL 4. Has auto-immune disease 5. Undergoing radiation therapy 6. Active urinary tract infection 7. Detrusor instability refractory to medication 8. Reduced bladder compliance as defined by a cystometrogram 9. Significant residual volume (greater than 100 ml) after voiding in which detrusor contraction is weak, when the bladder volume is greater than or equal to 250 ml 10. Has, had, or is suspected of having bladder cancer 11. History of bladder stones 12. Urethral stricture evidenced during cystourethroscopy 13. Has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia 14. Has a diathesis, hemophilia, or a bleeding disorder 15. Has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3 or higher 16. Had prior pelvic radiotherapy 17. Had a prior artificial urinary sphincter implanted 18. Has a neurogenic condition known to affect bladder/sphincter function

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
University of Colorado Denver Colorado Recruiting
CHI Health Research Center Omaha Nebraska Recruiting
Hôpital de la Conception - Marseille Marseille France Recruiting
CHU de Nantes Nantes France Recruiting
Pitié Salpêtrière University Hospital Paris Paris France Recruiting

More Uromedica trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04248283 on ClinicalTrials.gov ↗ ← All trials in the USA